Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07545772 · ClinicalTrials.gov registry record · Phase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
A Phase 2 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 342
- Enrollment target
NCT07545772: Recruiting Phase 2 study, sponsored by Eli Lilly and Company.
NCT07545772 is a Phase 2 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 342 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (157% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07545772, a Phase 2 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 342 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo. The study will last approximately 35 weeks.
Interventions
- DRUG Placebo
- DRUG LY3537031
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2026-04-29 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT07545772 shows while recruiting
NCT07545772 is an interventional study that assigns participants to a tested intervention. The registered 342 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (157% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07545772 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07545772 about?
NCT07545772 is a clinical study titled "A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)". The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared w...
What is the current status of trial NCT07545772?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 342 participants. The study started on 2026-04-29. Estimated completion is 2027-09.
What interventions are being tested in trial NCT07545772?
The interventions under investigation include: Placebo (DRUG), LY3537031 (DRUG).
Who is sponsoring clinical trial NCT07545772?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07545772's enrollment target sits among peer trials
342 136th of 2000 higher than 1,864 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
- NCT06544941 · 342 participants · NA
Improving Maternal Sleep and Mental Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI